OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Anderson on the GRIFFIN Study With D-RVd in Multiple Myeloma

April 18th 2020

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Dr. Nagalla on the Utility of DOACs in Cancer-Associated Thrombosis

April 18th 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Dr. Hamilton on the FDA Approval of Tucatinib in HER2+ Breast Cancer

April 17th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the FDA approval of tucatinib (Tukysa) in HER2-positive breast cancer.

Dr. Schmaier on Managing Cancer-Associated Thrombosis

April 17th 2020

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Dr. Kreitman on Ongoing Research With Moxetumomab Pasudotox in Hairy Cell Leukemia

April 17th 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).

Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC

April 17th 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Bradley on Evolving Therapeutic Strategies in MPNs

April 17th 2020

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Dr. Grossbard on the DYNAMO Study With Duvelisib in Follicular Lymphoma

April 17th 2020

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Dr. Morgan on Idecabtagene Vicleucel in Multiple Myeloma

April 17th 2020

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Bekaii-Saab on the Need for Umbrella Trials in Biliary Tract Cancer

April 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Dr. Parikh on Determining Transplant Eligibility in HCC

April 17th 2020

Neehar Parikh, MD, discusses criteria for determining transplant eligibility in hepatocellular carcinoma.

Dr. Choti on the Role of Upfront Surgery in Pancreatic Adenocarcinoma

April 17th 2020

Michael A. Choti, MD, discusses the role of upfront surgery in pancreatic adenocarcinoma.

Dr. Uzzo on Efforts to Improve Cancer Care Amidst the COVID-19 Crisis

April 16th 2020

Robert G. Uzzo, MD, MBA, FACS, shares efforts to improve cancer care amidst the COVID-19 crisis.

Dr. Braunstein on Considerations for Stem Cell Transplant Eligibility in Myeloma

April 16th 2020

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Dr. Hudson on the Utility of Liquid Biopsy in Lung Cancer

April 16th 2020

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Dr. Mesa on Treatment Advancements Made in MPNs

April 16th 2020

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.

Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma

April 16th 2020

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Dr. Cutler on Novel Preventive Strategies Against GVHD

April 16th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Dr. Rizvi on Brentuximab Vedotin Combinations in Hodgkin Lymphoma

April 16th 2020

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial Carcinoma

April 15th 2020

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.